SJS Investment Consulting
MBX icon

SJS Investment Consulting’s MBX Biosciences MBX Stock Holding History

SJS Investment Consulting’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$176 Buy
3
+1
+50% +$63 ﹤0.01% 2973
2026
Q2 		$111 Buy
+2
New +$70 ﹤0.01% 2591

Other funds holding MBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
NVP Associates
NVP Associates Menlo Park, California $282M AUM 85.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Aaron Wealth Advisors
Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $33.4B AUM 56.97% 1-Year Est. Return

SJS Investment Consulting's MBX Position: Q3 2026 in Review

SJS Investment Consulting increased its MBX Biosciences (MBX) stake by 50% in Q3 2026, buying an estimated $63 and bringing the position to 3 shares worth $176. The position accounts for ﹤0.01% of the portfolio, ranked #2973.

SJS Investment Consulting first reported a position in MBX in Q2 2026 and has held it in 2 quarters since. 130 funds tracked by Wall St. Rank hold MBX as of Q3 2026.

  • SJS Investment Consulting held 3 shares of MBX Biosciences worth $176 as of Q3 2026.
  • SJS Investment Consulting bought 1 MBX Biosciences share in Q3 2026, an estimated $63.
  • MBX Biosciences made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #2973 holding.
  • SJS Investment Consulting first reported a position in MBX Biosciences in Q2 2026 and has held it in 2 quarters since.
  • 130 funds tracked by Wall St. Rank held MBX Biosciences as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.